Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia

BACKGROUND: Acute myeloid leukemia (AML) is a fatal clonal hematopoietic malignancy, which results from the accumulation of several genetic aberrations in myeloid progenitor cells, with a worldwide 5-year survival prognosis of about 30%. Therefore, the development of more effective therapeutics with...

Descripción completa

Detalles Bibliográficos
Autores principales: Bäumer, Nicole, Scheller, Annika, Wittmann, Lisa, Faust, Andreas, Apel, Mara, Nimmagadda, Subbaiah Chary, Geyer, Christiane, Grunert, Katharina, Kellmann, Neele, Peipp, Matthias, Kailayangiri, Sareetha, Gutierrez Suburu, Matias Ezequiel, Strassert, Cristian A., Schenk, Mathias, Greune, Lilo, Rüter, Christian, Dersch, Petra, Hartmann, Wolfgang, Rossig, Claudia, Neri, Dario, Müller-Tidow, Carsten, Schwöppe, Christian, Schliemann, Christoph, Khandanpour, Cyrus, Lenz, Georg, Berdel, Wolfgang E., Bäumer, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716776/
https://www.ncbi.nlm.nih.gov/pubmed/36457063
http://dx.doi.org/10.1186/s13045-022-01390-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716776/
https://www.ncbi.nlm.nih.gov/pubmed/36457063
http://dx.doi.org/10.1186/s13045-022-01390-5

Ejemplares similares